Investment Highlights

As the first non-invasive, saliva-based glucose test for diabetes management, the Saliva Glucose Biosensor is a revolutionary technology that can free the 114 million diabetes patients in China from having to use painful and invasive blood monitoring devices to manage their condition, offering a better quality of life.

China has the world’s largest diabetes epidemic, with one quarter of the global diabetic population and close to 500 million people with prediabetes.

By eradicating the need for finger prick blood tests, the Saliva Glucose Biosensor will lead to improved glycemic control, better healthcare outcomes for patients and potentially massive cost savings for health systems.

The Saliva Glucose Biosensor is a platform technology and development has commenced to expand beyond its first application as a saliva glucose diagnostic test to include an entire portfolio of tests such as cancer markers, hormones, and allergens.

Contact

GBSG Investor Relations

info@gbsgreaterchina.com

News

Press Releases

Download Introductory Brochure

Complete the form to receive a copy of the GBSG Introductory Brochure.